DK1713458T5 - Fremgangsmåde til forstærkning af biotilgængeligheden af ospemifen - Google Patents

Fremgangsmåde til forstærkning af biotilgængeligheden af ospemifen

Info

Publication number
DK1713458T5
DK1713458T5 DK05701734T DK05701734T DK1713458T5 DK 1713458 T5 DK1713458 T5 DK 1713458T5 DK 05701734 T DK05701734 T DK 05701734T DK 05701734 T DK05701734 T DK 05701734T DK 1713458 T5 DK1713458 T5 DK 1713458T5
Authority
DK
Denmark
Prior art keywords
bioavailability
enhancing
ospemifene
compound
stereoisomer
Prior art date
Application number
DK05701734T
Other languages
Danish (da)
English (en)
Other versions
DK1713458T3 (da
Inventor
Markku Anttila
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1713458(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of DK1713458T3 publication Critical patent/DK1713458T3/da
Application granted granted Critical
Publication of DK1713458T5 publication Critical patent/DK1713458T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DK05701734T 2004-02-13 2005-01-14 Fremgangsmåde til forstærkning af biotilgængeligheden af ospemifen DK1713458T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene
PCT/FI2005/000018 WO2005077350A1 (en) 2004-02-13 2005-01-14 Method for enhancing the bioavailability of ospemifene

Publications (2)

Publication Number Publication Date
DK1713458T3 DK1713458T3 (da) 2008-07-07
DK1713458T5 true DK1713458T5 (da) 2008-09-29

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05701734T DK1713458T5 (da) 2004-02-13 2005-01-14 Fremgangsmåde til forstærkning af biotilgængeligheden af ospemifen

Country Status (23)

Country Link
US (5) US8236861B2 (OSRAM)
EP (1) EP1713458B1 (OSRAM)
JP (2) JP5577011B2 (OSRAM)
CN (1) CN1925847A (OSRAM)
AT (1) ATE387910T1 (OSRAM)
AU (1) AU2005211958B2 (OSRAM)
BE (1) BE2015C033I2 (OSRAM)
BR (1) BRPI0507661A (OSRAM)
CA (1) CA2556089C (OSRAM)
CY (2) CY1111014T1 (OSRAM)
DE (1) DE602005005165T2 (OSRAM)
DK (1) DK1713458T5 (OSRAM)
ES (1) ES2302177T3 (OSRAM)
FR (1) FR15C0041I2 (OSRAM)
HU (1) HUS1500030I1 (OSRAM)
LT (1) LTC1713458I2 (OSRAM)
LU (1) LU92736I2 (OSRAM)
MX (1) MXPA06009274A (OSRAM)
NO (2) NO337656B1 (OSRAM)
PL (1) PL1713458T3 (OSRAM)
PT (1) PT1713458E (OSRAM)
RU (1) RU2385716C2 (OSRAM)
WO (1) WO2005077350A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
AU2005237274B2 (en) 2004-05-04 2011-02-17 Hormos Medical Ltd Novel oral formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
RU2008122993A (ru) * 2005-11-09 2009-12-20 Хормос Медикал Лтд. (Fi) Препаративные формы фиспемифена
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA018066B1 (ru) * 2005-11-28 2013-05-30 Джи Ти Икс, ИНК. Агент, связывающийся с ядерными рецепторами
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
JP5363344B2 (ja) * 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
LT3790548T (lt) 2018-05-11 2024-01-10 Xenon Pharmaceuticals Inc. Potencialu aktyvuojamo kalio kanalų atvėriklio biologinio prieinamumo ir kontakto padidinimo būdai
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
GEAP202415942A (en) 2019-11-08 2024-10-28 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
GEAP202416348A (en) 2021-02-09 2024-01-10 Xenon Pharmaceuticals Inc Methods and uses for treating anhedonia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
US6219674B1 (en) 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
EP1377912A4 (en) 2001-02-22 2007-11-14 Classen Immunotherapies Inc Improved computer algorithms and methods for enhancing product safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
EP1509215B1 (en) 2002-06-06 2006-11-02 Hormos Medical Ltd. Treatment or prevention of urogenital atrophy and its symptoms in women
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Also Published As

Publication number Publication date
BRPI0507661A (pt) 2007-07-17
LTC1713458I2 (lt) 2017-06-26
LTPA2015023I1 (lt) 2015-08-25
DK1713458T3 (da) 2008-07-07
NO20063960L (no) 2006-11-03
RU2385716C2 (ru) 2010-04-10
US20160101065A1 (en) 2016-04-14
EP1713458B1 (en) 2008-03-05
JP6023119B2 (ja) 2016-11-09
RU2006132719A (ru) 2008-03-20
BE2015C033I2 (OSRAM) 2024-08-08
JP2007522190A (ja) 2007-08-09
LU92736I2 (fr) 2015-08-10
US8470890B2 (en) 2013-06-25
CY2015027I2 (el) 2016-04-13
HUS1500030I1 (hu) 2015-08-28
EP1713458A1 (en) 2006-10-25
NO20151603L (no) 2006-11-03
NO339190B1 (no) 2016-11-14
US20140303259A1 (en) 2014-10-09
DE602005005165T2 (de) 2009-04-30
FR15C0041I1 (OSRAM) 2015-07-17
CA2556089A1 (en) 2005-08-25
PT1713458E (pt) 2008-05-07
FR15C0041I2 (fr) 2015-11-13
WO2005077350A1 (en) 2005-08-25
ES2302177T3 (es) 2008-07-01
MXPA06009274A (es) 2007-04-16
AU2005211958B2 (en) 2010-11-25
JP5577011B2 (ja) 2014-08-20
CA2556089C (en) 2013-04-02
US8236861B2 (en) 2012-08-07
CY2015027I1 (el) 2016-04-13
US9855224B2 (en) 2018-01-02
US20120270952A1 (en) 2012-10-25
CY1111014T1 (el) 2015-06-11
CN1925847A (zh) 2007-03-07
JP2014141533A (ja) 2014-08-07
PL1713458T3 (pl) 2008-08-29
US20130324614A1 (en) 2013-12-05
ATE387910T1 (de) 2008-03-15
US8772353B2 (en) 2014-07-08
NO337656B1 (no) 2016-05-23
US9241915B2 (en) 2016-01-26
AU2005211958A1 (en) 2005-08-25
DE602005005165D1 (de) 2008-04-17
US20050182143A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
HUS1500030I1 (hu) Eljárás az ospemifene biohasznosulásának javítására
CY1111689T1 (el) Στερεες φαρμακοτεχνικες μορφες ospemifene
AR107474A2 (es) Proceso para la preparación de un ácido de 1,2,4-oxadiazol benzoico
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
ATE433988T1 (de) Phosphoramidatderivate
EA200800147A1 (ru) Способ получения олмесартан медоксомила
NZ789146A (en) Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
AR051754A1 (es) Metodos para preparar compuestos de indazol
EA201100994A1 (ru) Способ получения производных бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ лечения или профилактики ретровирусных инфекций с ее помощью
EA200970449A1 (ru) Композиции ацетаминофена, обладающие сведенными к минимуму побочными эффектами, включая пониженную гепатотоксичность
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
EA200801619A1 (ru) Способ улучшения фармакокинетики ингибиторов интегразы вич (варианты), набор и фармацевтическая композиция (варианты)
NO20082181L (no) Formuleringer av Fispemifen
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2009011901A3 (en) Methods for promoting wakefulness
DK1791537T3 (da) 3-arylthioindol-2-carboxamidderivater og analoger deraf som inhibitorer af casein-kinase
CR10506A (es) Derivados de acido fenilacetico
BRPI0512251A (pt) método enantioseletivo para separação de derivados do ácido 2-trifluormetil-2h-cromeno-3-carboxìlico substituìdo
WO2007133476A3 (en) Competitive substrate inhibition to increase drug bioavailability
AP2277A (en) Process for production of 1,2,2,2-tertafluoro ethyl difluoro methyl ether.